EA200500984A1 - Производные 3-замещённого-4-пиримидона - Google Patents

Производные 3-замещённого-4-пиримидона

Info

Publication number
EA200500984A1
EA200500984A1 EA200500984A EA200500984A EA200500984A1 EA 200500984 A1 EA200500984 A1 EA 200500984A1 EA 200500984 A EA200500984 A EA 200500984A EA 200500984 A EA200500984 A EA 200500984A EA 200500984 A1 EA200500984 A1 EA 200500984A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituted
ring
alkyl group
nitrogen atom
atom
Prior art date
Application number
EA200500984A
Other languages
English (en)
Other versions
EA009027B1 (ru
Inventor
Йосихиро Усуи
Масахиро Окуяма
Токуси Ханано
Original Assignee
Мицубиси Фарма Корпорейшн
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мицубиси Фарма Корпорейшн, Санофи-Авентис filed Critical Мицубиси Фарма Корпорейшн
Publication of EA200500984A1 publication Critical patent/EA200500984A1/ru
Publication of EA009027B1 publication Critical patent/EA009027B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Производное пиримидона формулы (I) или его соль, или их сольват или их гидрат, пригодные для использования в качестве ингибитора тау-протеинкиназы 1, в котором X представляет собой CH или атом азота, Rпредставляет собой C-C-алкильную группу, которая может быть замещенной, Rпредставляет собой C-C-алкильную группу, которая может быть замещенной, бензольное кольцо, которое может быть замещенным, нафталиновое кольцо, которое может быть замещенным, индановое кольцо, которое может быть замещенным, тетрагидронафталиновое кольцо, которое может быть замещенным, или необязательно замещенное гетероциклическое кольцо, имеющее 1-4 гетероатома, выбранных из группы, состоящей из атома кислорода, атома серы и атома азота, и имеющее, в целом, 5-10 атомов, составляющих кольцо.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500984A 2002-12-16 2003-12-12 Производные 3-замещенного-4-пиримидона EA009027B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002383301 2002-12-16
JP2002383300 2002-12-16
PCT/JP2003/015968 WO2004055007A1 (en) 2002-12-16 2003-12-12 3-substituted-4-pyrimidone derivatives

Publications (2)

Publication Number Publication Date
EA200500984A1 true EA200500984A1 (ru) 2005-12-29
EA009027B1 EA009027B1 (ru) 2007-10-26

Family

ID=32599307

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500984A EA009027B1 (ru) 2002-12-16 2003-12-12 Производные 3-замещенного-4-пиримидона

Country Status (13)

Country Link
US (1) US7683069B2 (ru)
EP (1) EP1572681B1 (ru)
JP (1) JP4616003B2 (ru)
KR (1) KR100956052B1 (ru)
CN (1) CN1726209B (ru)
BR (1) BR0316785A (ru)
CA (1) CA2510170C (ru)
EA (1) EA009027B1 (ru)
MX (1) MXPA05006394A (ru)
NO (1) NO20053449L (ru)
NZ (1) NZ541074A (ru)
WO (1) WO2004055007A1 (ru)
ZA (1) ZA200505258B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
PL368816A1 (en) 2001-09-21 2005-04-04 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
EA007576B1 (ru) 2001-09-21 2006-12-29 Мицубиси Фарма Корпорейшн Производные 3-замещенных 4-пиримидонов
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
WO2006041405A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
JP2008516945A (ja) * 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
US20100292205A1 (en) * 2006-08-23 2010-11-18 Pfizer Inc. Pyrimidone Compounds As GSK-3 Inhibitors
EP1992625A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
EP1992621A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992620A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992624A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
JP5535310B2 (ja) * 2009-08-13 2014-07-02 田辺三菱製薬株式会社 タウプロテインキナーゼ１阻害剤としてのピリミドン誘導体

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559099B2 (ru) 1972-08-07 1980-03-07
JPS4935633A (ru) 1972-08-09 1974-04-02
JPS4935632A (ru) 1972-08-10 1974-04-02
JPS5124008B2 (ru) 1972-08-10 1976-07-21
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) * 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
IN151188B (ru) * 1978-02-13 1983-03-05 Smith Kline French Lab
US4507302A (en) * 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) * 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
EP0354179B1 (de) 1988-07-29 1994-08-17 Ciba-Geigy Ag Thiouracile als Stabilisatoren für chlorhaltige Polymerisate
ES2136654T3 (es) 1991-12-06 1999-12-01 Max Planck Gesellschaft Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer.
DE4206145A1 (de) * 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
CA2174080A1 (en) * 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AR038955A1 (es) 1996-12-05 2005-02-02 Amgen Inc Compuestos de pirimidinona y piridona sustituidos y metodos para su uso
NZ335997A (en) 1996-12-05 2001-08-31 Amgen Inc Substituted pyrimidine compounds for treating TNF and interleukin diseases
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO1998024780A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
EP0976745B1 (en) * 1997-03-26 2003-08-13 Taisho Pharmaceutical Co., Ltd 4-tetrahydropyridylpyrimidine derivatives
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
BR0108611A (pt) * 2000-02-25 2003-05-06 Hoffmann La Roche Moduladores de receptor de adenosina
EP1136482A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
WO2001070728A1 (en) * 2000-03-23 2001-09-27 Sanofi-Synthelabo 2-[nitrogen-heterocyclic]pyrimidone derivatives
BRPI0111596B8 (pt) * 2000-06-12 2022-07-26 Eisai Co Ltd Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto
EA007576B1 (ru) * 2001-09-21 2006-12-29 Мицубиси Фарма Корпорейшн Производные 3-замещенных 4-пиримидонов
PL368816A1 (en) * 2001-09-21 2005-04-04 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
US20070142409A1 (en) 2007-06-21
CN1726209A (zh) 2006-01-25
KR20050099496A (ko) 2005-10-13
KR100956052B1 (ko) 2010-05-06
AU2003285777A8 (en) 2004-07-09
EP1572681A1 (en) 2005-09-14
BR0316785A (pt) 2005-10-25
ZA200505258B (en) 2006-09-27
US7683069B2 (en) 2010-03-23
WO2004055007A1 (en) 2004-07-01
AU2003285777A1 (en) 2004-07-09
EP1572681B1 (en) 2014-01-22
CA2510170C (en) 2011-05-24
CA2510170A1 (en) 2004-07-01
JP4616003B2 (ja) 2011-01-19
NO20053449L (no) 2005-07-15
MXPA05006394A (es) 2007-04-16
NZ541074A (en) 2008-04-30
EA009027B1 (ru) 2007-10-26
JP2006510684A (ja) 2006-03-30
CN1726209B (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
EA200400452A1 (ru) Производные 3-замещенных 4-пиримидонов
EA200400453A1 (ru) Производные 3-замещенных 4-пиримидонов
NO20053449L (no) 3-substituerte 4-pyrimidonderivater
ME00411B (me) Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
HRP20050628A2 (en) Substituted benzoyl derivatives uses as herbicides
EA200401172A1 (ru) Производные n-[фенил(пиперидин-2-ил)метил]бензамида, способ их получения и их применение в терапии
DE60113080D1 (de) 4-amino-5-cyano-2-anilino-pyrimidin-derivate zur verwendung als inhibitoren von zellzyklus-kinasen
EA200300763A1 (ru) Пиридиновые ингибиторы матриксных металлопротеиназ
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
ES2189968T3 (es) Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS.
DK0982992T3 (da) Anvendelse af thienopyrimidiner som fungicider
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
BRPI0407841A (pt) inibidores heterocìclicos de quinase
NO305287B1 (no) AMPA antagonister
EA200200523A1 (ru) Новые разветвленные замещенные аминопроизводные 3-амино-1-фенил-1h[1,2,4]триазола, способы их получения и содержащие их фармацевтические композиции
BRPI0510075A (pt) benzoxazocinas e seu uso terapêutico como inibidores de reabsorção de monoamina
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler
ATE500243T1 (de) Carbonsäureamidverbindung und deren verwendung
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase
EA200500138A1 (ru) Фунгицидные смеси на базе дитианона
EA199800693A1 (ru) Азольные соединения с противогрибковой активностью, предназначенные для человека и животных
ATE340175T1 (de) Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase
TH65446A (th) อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3
TH102358B (th) อนุพันธ์ 4-ไพริมิโดนซึ่งถูกแทนที่ที่ตำแหน่ง 3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU